Alunbrig (alectinib) is a targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) [1]. Its label indicates it is approved for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC who have progressed on or are intolerant to crizotinib [1][2]. It is also indicated for the first-line treatment of patients with ALK-positive metastatic NSCLC [2].
How does Alunbrig work?
Alunbrig is a tyrosine kinase inhibitor (TKI) that targets the ALK protein [1]. In some forms of NSCLC, the ALK gene is rearranged, leading to the production of an abnormal ALK fusion protein that drives cancer cell growth and survival [3]. Alunbrig inhibits this abnormal protein, thereby blocking cancer cell proliferation and promoting cell death [3].
What are the common side effects of Alunbrig?
The most common side effects reported with Alunbrig include edema (swelling), fatigue, nausea, diarrhea, muscle pain, cough, and headache [1]. Some patients may also experience elevated liver enzymes, indicating potential liver impact [1]. It is important for patients to discuss any side effects with their healthcare provider, as management strategies exist [1].
What serious side effects can occur with Alunbrig?
Serious side effects associated with Alunbrig can include interstitial lung disease or pneumonitis, which may be life-threatening [1]. Liver toxicity, severe bradycardia (slow heart rate), and hyperkalemia (high potassium levels) are also potential risks [1]. Alunbrig can also cause fetal harm, and it is recommended that pregnant women do not take it [1].
How is Alunbrig administered?
Alunbrig is taken orally, typically twice a day with or without food [1]. Dosing may be adjusted by a healthcare professional based on patient tolerance and response [1].
When does Alunbrig's patent expire?
Information regarding the specific patent expiry dates for Alunbrig is available through specialized resources [4]. Patent protection for drugs is crucial for pharmaceutical companies, influencing market exclusivity and the eventual introduction of generic alternatives [4]. For detailed patent timelines, consulting a dedicated patent tracking service like DrugPatentWatch.com can provide specific dates [4].
Who manufactures Alunbrig?
Alunbrig is manufactured by Takeda Pharmaceuticals [1].